January 2025

BarMatin^TM in Canada authorized (confined permission):
The Canadian Food Inspection Agency (CFIA) has permitted BarMatin^TM according to Directive 2000-07 for outdoor trials in Canada in the provinces Saskatchewan and Manitoba (no. 25-AGQ1-406-BAR). With the resulting biosafety assessment data, an unconfined permission according to Directive 94-08 will be submitted.

November 2024

Preclinical study proved: Thaumatin has a preventive effect against gastric cancer:

80% of all human beings carry the bacteria Helicobacter pylori inside their gastrointestinal tract and therefore have an increased risk for suffering from gastric cancer, which has a high mortality rate. Effective vaccination is currently not possible or only with strong side effects.
Digested peptides from thaumatin efficiently inhibit the Helicobacter pylori-induced release of the metastases-associated pro-inflammatory cytokine IL-17A by blocking the bitter taste intra-gastrointestinal receptor TAS2R16 (reduction is about 90%), which plays a key role during cancer pathogenesis. Thus, thaumatin has, beyond its excellent sweetening features, a huge potential as a prophylaxis against gastric cancer development even in very low intake dosages (see Richter et al., (2024) Gastric digestion of the sweet-tasting plant protein thaumatin releases bitter peptides that reduce H. pylori induced pro-inflammatory IL-17A release via the TAS2R16 bitter taste receptor. Food Chem (448): 1–10)).

January 2025

BarMatin^TM in Canada authorized (confined permission):
The Canadian Food Inspection Agency (CFIA) has permitted BarMatin^TM according to Directive 2000-07 for outdoor trials in Canada in the provinces Saskatchewan and Manitoba (no. 25-AGQ1-406-BAR). With the resulting biosafety assessment data, an unconfined permission according to Directive 94-08 will be submitted.

November 2024

Preclinical study proved: Thaumatin has a preventive effect against gastric cancer:

80% of all human beings carry the bacteria Helicobacter pylori inside their gastrointestinal tract and therefore have an increased risk for suffering from gastric cancer, which has a high mortality rate. Effective vaccination is currently not possible or only with strong side effects.
Digested peptides from thaumatin efficiently inhibit the Helicobacter pylori-induced release of the metastases-associated pro-inflammatory cytokine IL-17A by blocking the bitter taste intra-gastrointestinal receptor TAS2R16 (reduction is about 90%), which plays a key role during cancer pathogenesis. Thus, thaumatin has, beyond its excellent sweetening features, a huge potential as a prophylaxis against gastric cancer development even in very low intake dosages (see Richter et al., (2024) Gastric digestion of the sweet-tasting plant protein thaumatin releases bitter peptides that reduce H. pylori induced pro-inflammatory IL-17A release via the TAS2R16 bitter taste receptor. Food Chem (448): 1–10)).